| name | ppgl-hnpgl-intervention-indication |
| description | Assesses specific clinical indications warranting surgical resection or radiation therapy for head and neck paraganglioma. Recommends intervention for tympanic PGL with hearing loss, jugular bulb PGL with pulsatile tinnitus, significant skull base compression, catecholamine production, rapid growth, or metastasis; triggers include 'HNPGL patient develops neurological symptoms,' 'Tumor shows rapid growth on serial imaging,' 'Functional testing reveals catecholamine overproduction in HNPGL'. |
Head/Neck PGL Intervention Indication Assessment
STEP 1 — Gather Information
Collect clinical history (hearing loss, pulsatile tinnitus, cranial nerve deficits, neurological symptoms), physical exam, biochemical testing (plasma-free fractionated metanephrines, normetanephrines, 3-MT), imaging (contrast-enhanced MRI of head and neck, skull base CT, whole-body MRI with PET/CT if indicated), serial imaging for growth rate, and genetic testing for SDHD/SDHB if familial or multifocal; compile findings to determine presence of high-risk features.
STEP 2 — Rule In / Rule Out
If any high-risk feature is present — tympanic PGL with hearing loss, jugular bulb PGL with pulsatile tinnitus, significant skull base compression, catecholamine production, documented rapid growth on serial imaging, or metastasis — rule in for intervention; otherwise rule out for surveillance. Proceed to classification if ruled in; otherwise recommend surveillance and routine follow‑up imaging.
STEP 3 — Classify or Stratify
Sub‑classify by tumor location (tympanic, jugular bulb, carotid body, vagus nerve) and functionality (catecholamine‑producing vs non‑producing), and assess degree of skull base compression or growth rate; determine whether surgery, radiation, or a multidisciplinary approach is indicated based on the dominant risk factor.
STEP 4 — Decide
For tympanic PGL with hearing loss or jugular bulb PGL with pulsatile tinnitus, recommend surgical resection; for significant skull base compression or catecholamine production, consider surgery or primary radiation therapy; for rapid growth or metastasis, advise a multidisciplinary plan including surgery, stereotactic radiotherapy, radionuclide therapy (131I‑MIBG or 177Lu‑DOTATATE), or chemotherapy as appropriate; document decision and obtain informed consent.
Clinical Guardrails / Mimics / Pitfalls
Avoid fine‑needle cytology due to risk of hypertensive crisis and diagnostic inaccuracy; do not intervene in asymptomatic, non‑growing tumors <1 cm without high‑risk features; ensure preoperative α‑blockade if catecholamine excess is confirmed; monitor postoperative cranial nerve function; radiation may cause xerostomia, necrosis, or secondary malignancy; genetic testing results should guide surveillance intensity but are not an immediate indication for intervention.
Concrete Clinical Example
A 50‑year‑old presents with progressive unilateral hearing loss; MRI shows a 1.2 cm tympanic PGL eroding the bony septum with interval growth over 8 months; audiometry confirms conductive hearing loss; biochemical testing is normal. Decision: surgical resection recommended.
Source: Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025, Japan Endocrine Society, 2025, DOI:10.1507/endocrj.EJ25-0165
